Source comparison
Tesamorelin vs Related Growth Hormone Injection Therapies
Tesamorelin is best understood as one growth hormone-axis therapy among several different categories. It is a GHRH analog with an approved HIV-associated lipodystrophy indication, while somatropin is recombinant growth hormone with different indications and ri
This comparison does not assign a generated winner or score.
- Tesamorelin is best understood as one growth hormone-axis therapy among several different categories. It is a GHRH analog with an approved HIV-associated lipodystrophy indication, while somatropin is recombinant growth hormone with different indications and risks [1], [12].
- CJC-1295 is also a GHRH analog studied for growth hormone and IGF-1 stimulation in human research, but it does not share tesamorelin’s FDA-approved indication for HIV-associated abdominal fat reduction [13]. Ipamorelin is a growth hormone secretagogue discussed in research contexts, but it acts through different receptor biology and lacks the same approved tesamorelin indication 14.
- Tesamorelin
- GHRH receptor activation at the pituitary gland [1], [4]
- FDA-approved for excess abdominal fat in adults with HIV-associated lipodystrophy [1], [2]
- Strongest support is for the labeled indication.
- Somatropin
- Direct recombinant growth hormone [12]
- FDA-approved products exist for specific indications [12]
- Not interchangeable with tesamorelin; different dosing, risks, and indications.
- CJC-1295
- Long-acting GHRH analog studied for GH/IGF-1 stimulation [13]
- Human research exists, but no equivalent FDA-approved HIV lipodystrophy indication [13]
- Mechanistically related but regulatory and evidence status differ.
- Ipamorelin
- Growth hormone secretagogue research pathway [14]
- Research context; not equivalent to tesamorelin’s labeled use [14]
- Related only broadly through GH-axis interest.